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Abstract 
Cardiovascular diseases have emerged as a major concern since they are the first cause of 
death in developed countries. The advent of percutaneous trans luminal coronary 
angioplasty consisted in an alternative to invasive surgery. Especially the introduction of 
cardiovascular stents has significantly meliorated the potential of angioplasty, e.g. with the 
use of drug eluting and bio absorbable stents. Still, restenosis remains a major implant-
related complication and can imply re intervention. Therefore, research has focused on 
limiting and/or avoiding restenosis by investigating the field of fully biodegradable stents. 
The main aspect of this project is to focus on the fabrication of PLLA films to then 
characterise them chemically, physically and mechanically to be able to use this material in 
the future as a totally biodegradable cardiovascular stent. 
The first step was to choose which film fabrication process to use in order to obtain the best 
aspect and properties for our application. 
Then enhance the process by focusing on ameliorating properties and surface aspect of the 
film. 
The following step was to create carboxyl groups as a preliminary step for bio 
functionalization. This was done by different surface treatment: oxygen plasma, ozone and 
sodium hydroxide. 
And finally we compared the degradation of selected films with a fully bio absorbable stent 
made of the same polymer.  
Optimal film fabrication was obtained with solvent casting using chloroform as solvent with 
2,5g of PLLA PL65 and 70ml of chloroform. To improve properties and surface aspect, 
thermal treatment were carried out pre and post fabrication. Films had less bubbles but were 
less transparent and more rigid due to higher cristallinity. Mechanical properties increased 
(Young modulus and tensile strength) and residual chloroform evaporated totally making 
films non cytotoxic.  
Optimal surface treatment was obtained with plasma. 
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1. Introduction 
Cardiovascular diseases have become an important problem especially in developed 
countries where medical advances have led to increasing life expectancy. According to the 
World Health, an estimated 17 million people die of cardiovascular diseases particularly 
heart attacks and strokes, every year [1]. The Centre for Disease Control and Prevention 
reported more than two million heart attacks and strokes a year resulting in 2.200 deaths per 
day in the United States. Major adverse cardiac events including heart attack and 
cerebrovascular accidents, are caused by the presence of an atherosclerotic clot which 
blocks the blood flow, impeding the delivery of oxygen and nutrients to the muscles. 
Atherosclerosis is a physiological phenomenon which can display different severity levels. 
Lifestyles can therefore be both a cause and a solution to cardiovascular issues. Arteries are 
blood vessels that carry oxygenated blood away from the heart and supply the body with 
oxygen. In case of atherosclerosis, the artery is clogged up, so the blood is blocked and 
cannot provide oxygen to the muscle.  
 
Figure1. Atherosclerosis, fat deposit blocking blood flow [2] 
 Common habits like smoking, sedentary lifestyles, or fat diet are a major factor in 
cardiovascular problems. But after effective artery narrowing, medical treatment has to be 
followed.  
Surgery has rapidly been replaced by percutaneous transluminal coronary angioplasty 
consisting in dilating the narrowed artery [3].  Since 1977, this technique is constantly 
evolving especially thanks to intravascular implants, called stents. These small mesh tubes 
have brought important advances in the field of heart intervention. Consequently, medical 
research focuses on the improvement of stents properties by enhancing material 
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biocompatibility and by developing new biomaterials in order to limit the associated 
complications.   
 
Figure2.Bio absorbable Stent [4] 
1.1. Biological requirements 
1.1.1. Artery structure 
Arteries are composed of three major layers depending on the cell phenotype as seen. 
- Adventice: the most external layer composed of connective tissue, fibroblasts, also called 
tunica external 
-  Tunica media: composed of elastic tissue and smooth muscle cells (SMC) 
 -Tunica intima: containing elastic and connective tissue, endothelial cells (EC), in contact 
with the hollow internal cavity in which the blood flows: the lumen. 
  
Figure3. Artery layers [5] 
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The cells that most interact when there is an artery injury, like atherosclerosis, are SMC’s 
and EC’s. Smooth muscle cells are muscle tissue that contract involuntarily. They are 
surrounded by the extern basal lamina, and are located in the media, where there is no 
fibroblast. SMC’s synthesises collagen, elastin and some extra cellular matrix (ECM) 
molecules. In response to growth factors produced by endothelial cells, muscle cells can 
proliferate and migrate until the intima layer. This is an important characteristic of the normal 
vascular surface reparation, because the similar pathologic process occurs in 
atherosclerosis and needs to be avoided [6]. 
 
Figure4. Smooth muscle cells [7] 
Endothelial cells are the inner lining of blood vessel and serve as the cellular interface 
between the circulating blood and the vessel wall. The upper surface is in contact with the 
lumen and the bottom surface is fixed to a basal lamina which is composed of collagen. The 
endothelium is an epithelial tissue which can support high mechanical stresses and 
generates the basal lamina. The latter adds mechanical resistance. Endothelial cells are 
polarised cells involved in many aspects of vascular biology, including inflammation and 
angiogenesis. The recruitment of leukocytes (white blood cell) into inflammatory tissues is 
regulated by the interactions between blood cells and endothelial cells. Endothelial-leukocyte 
cell adhesion plays a major role in cellular communication and regulation, and is of 
fundamental importance in the development and maintenance of tissues. Atherosclerosis, 
ulcer, myocardial infarction, stroke, and other inflammatory processes are all related to, and 
dependent of this endothelial-leukocyte adhesion process. Endothelial cells also inhibit blood 
coagulation [8]. 
 
Figure5. Endothelial cells [9] 
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1.1.2. Cardiovascular diseases 
Cardiovascular diseases are mostly caused by atherosclerosis which is a physiologic 
phenomenon beginning at the embryonic stage and which grows with the ageing of arteries. 
This disease is occurs due to genetic predisposition and also the lifestyle of the person. 
Depending on how bad the atherosclerosis is, it can lead to stenosis or even thrombosis 
which then leads to death in most cases. 
Atherosclerosis 
Atherosclerosis begins with a linear deposit of fat on the intima which is the region between 
endothelium lining and the smooth muscle cells wall (media), without changing the blood 
flow. But then intima swells and increases the proliferation of smooth muscle cells and 
connective tissue. This can grow and lead to the formation of an instable and inflammatory 
plaque called atheroma [10].This plaque is composed of lipids (cholesterol crystals), calcium, 
fibrinogen and platelets, smooth muscle cells constituting a fibrous layer, and other blood 
cells. In the atheroma, cholesterol only constitutes 10% of the plaque whereas calcium and 
fibrinogen contribute 70% and makes the plaque hard and obstructs the blood flow. It can 
narrow the internal diameter of the artery which may cause a tiny clot to form which then 
obstructs the blood flow [11].  
This pathology can generate two main complications. The first one is the long-term evolution 
due to a slow growth of the plaque leading to final obstruction. The second one is a quick 
and acute complication corresponding to the rupture of endothelium. The resulting breach is 
obstructed by blood platelet aggregation which leads to the formation of a blood clot. This 
can obstruct the injured artery or detach and obstruct another vessel. 
Stenosis and thrombosis 
The development of atherosclerotic plaque leads to the increasing obstruction of the artery 
lumen, causing problems in the area beneath (chest pains, cramp after walking for example). 
This phenomenon is known as stenosis. Coronary thrombosis is a term used to describe the 
blockage of a coronary artery secondary to blood clotting within the artery. Thrombosis of 
coronary arteries occurs when the opening, or lumen, of the artery becomes so small that 
the blood flow through the narrowed segment slows down, allowing the blood to clot in the 
artery [12]. Thrombosis of a coronary artery can lead to a heart attack if not treated. 
Additionally, this plaque is fragile in surface leading to the possible fragment detachments 
that can block other smaller arteries in the brain (hemiplegia), the heart (heart attack) or 
lungs (pulmonary embolism). 
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1.2. State of the art 
1.2.1. History leading up to the use of stents 
The first successful operation to tackle atherosclerosis was to bypass the arterial stenosis by 
grafting arteries from elsewhere in the body to the coronary arteries [13].But this solution is 
very risky, tricky and expensive. Even after a successful operation many complications can 
occur such as infections, loss of kidney functions, brain complications or heart attacks. It 
also possesses the disadvantage of clotting and therefore further restenosis to the vessel 
[14]. Then, in the 1970s, angioplasty was introduced by Charles Dotter and then performed 
for the first time by Andreas Gruentzig in 1977. This technique consists in passing a deflated 
balloon through the blood vessels and then inflating it to open up the artery [15]. . But with 
this technique, there is still 30 to 50 % restenosis, recurrence of the stenosis, after the 
operation as well as elastic recoil and inflammation. [16]. A stent may or may not be inserted 
at the time of ballooning to ensure the vessel remains open. The restenosis is much lower 
after stent implantation 20 to 30 % [17][18]. 
 
Figure6. Stent implantation by angioplasty with expandable balloon [19] 
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1.2.2. Coronary stents 
Bare metal stents (BMS) introduced in 1986 served as mechanical scaffolds to prevent 
elastic recoil, and negative remodelling. BMS brought important advantages over balloon 
angioplasty alone with major adverse cardiac events, such as repeated revascularization, 
angiographic restenosis and reclusion.   
However, these events are still not infrequent [20]. Also, long-term endothelial dysfunction, 
delayed reendothelialization, thrombogenicity, permanent physical irritation and chronic 
inflammatory local reactions can be observed [21]. These reactions are factors that increase 
the risks of restenosis. 
To try to reduce further the rate of in stent restenosis, drug eluting stents, DES were brought 
into play at the beginning of the century. DESs are coated in polymeric material that releases 
drugs locally. Depending on the chosen polymers, they can completely degrade by the time 
the drug has been released, but the metallic stent remains [22]. The restenosis is brought 
down to 10 per cent in this case [23]. But the use of drugs in the vessels also hinders the 
natural healing process of the body and can also lead to late stent thrombosis [24]. 
This leads to look for other solutions like totally biodegradable stents made of polymer. 
Coronary dissections are effectively contained by stent insertion and undergo a healing 
process, with the majority of cardiac events occurring in the first 6 months. In stent 
restenosis also occurs within the first 6 months [25]. . Therefore, the clinical need for stent 
scaffolding is limited after this period. Considering the short-term need and the potential for 
long-term complications with metallic stents, stents made of biodegradable materials may be 
an ideal alternative. 
1.2.3. Fully Biodegradable Stents 
Stack et al [26], at Duke University, developed the first biodegradable stent and implanted it 
in animals. A polymer of poly-L-lactide was used for this prototype stent.  
The stent was almost completely degraded by 9 months. Clinical research with this device 
remained limited, despite the presence of minimal thrombosis and a limited inflammatory 
response in these early animal implants. 
In 2000, Tamai et al. [27] reported the first coronary clinical experience with a biodegradable 
polylactide stent. Poly-L-lactic acid is the most famous polymer used to design 
biodegradable stents in tissue engineering and drug-delivery due to its biodegradability and 
good mechanical properties.  
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This report focuses on the immediate and 6 month results after the implantation of a 
biodegradable PLLA stent in humans. This biodegradable stent combines the features of a 
thermal self-expandable and a balloon expandable A total of 25 stents were successfully 
implanted in 19 lesions in 15 patients, and angiographic success was achieved in all 
procedures. No stent thrombosis and no major cardiac event occurred within 30 days. The 
study proved PLLA stent to be safe in human coronary arteries. In the study, no stent 
thrombosis and no major cardiac event occurred within the first 6 months, meaning that 
there were no deaths, heart attacks, or coronary artery bypass surgeries. Full degradation 
took 18-24 months [27]. 
One concern with a biodegradable stent is whether stent degradation occurs in a reasonable 
time period. To reduce restenosis in humans, stents must maintain their scaffolding strength 
for over 6 months to overcome late vessel remodelling [29]. 
But polymeric biodegradable stents have demonstrated several limitations. Compared with 
metallic stents, radial strength is lower and may result in early recoil post-implantation [29]. 
While bio absorbable stents may potentially be the ideal stent, further clinical studies and 
developments are necessary. The right balance between absorption and radial strength 
must be obtained, and inflammation must be prevented at the same time. 
1.2.4. Stent properties and polymer selection 
It is necessary to choose a biodegradable polymer which has all the properties necessary for 
stents implants.  So the selected polymer needs to allow high scaffolding which means it 
needs to provide strong mechanical support to the vessel wall thanks to a high Young 
modulus, E. Our polymer must also have a high expansion ratio seeing as the stent must 
undergo sufficient expansion and conform to the vessel wall. This is highlighted by a high 
ultimate tensile strength, UTS. Other important properties are excellent corrosion resistance, 
good biocompatibility and thrombo-resistivity [38]. 
The manufacturing cost and the functionalization are also important factors in our choice of 
material. Indeed, the stent material should support functionalization, if necessary, in order to 
enhance endothelial cell adhesion and recover arteries functionality. 
Fully biodegradable polymeric stents are very recent and very few studies have taken place. 
All of them are resumed in Table 1. 
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Polymers State of 
investigation 
Clinical 
advantages 
Clinical disadvantages References Properties 
IGAKI-TAMAI 
stent: PLLA 
Long human 
studies (more 
than 10 
years); CE 
mark for 
peripheral 
arteries since 
2007 
Non-drug 
eluting (PLLA 
without drug: very 
close to our 
application); a low 
complication rate; 
survival rates free 
from death, 
cardiac death 
Concerns have arisen 
about the ability to 
apply heat, to self-
expand the stent 
without causing 
possible necrosis of the 
artery wall leading to 
excessive intimal 
hyperplasia or increase 
platelet adhesion 
leading to stenosis 
 
[30][31][32] 
TS= 15-
150MPa; 
E = 2,7-4,14 
GPa; 
Degradable in 
18-24 month 
Paclitaxel-
eluting PLLA 
Non-human 
studies 
reduced 
proliferation and 
stenosis after 
vascular 
intervention 
  [30][33] TS= 15-
150MPa; 
E = 2,7-4,14 
GPa 
ABSORB: PLLA 
(and a PDLLA 
coating with 
evrolimus 
inside) 
CE mark for 
coronary 
arteries since 
2011 
reduced in-stent 
late loss and a 
low 
MACE rate of 
4.4%; comparable 
acute vessel 
recoil to the EES; 
no stenosis has 
been observed up 
to 3 years follow-
up 
 
  
[30][34][35] 
TS= 15-
150MPa; 
E = 2,7-4,14 
GPa 
Degradable in 
24 month; 
radial support 
during 3 
months 
REVA stent: 
Tyrosine 
polycarbonate 
FIM in 2011 Improve acute 
recoil; minimal 
vessel shrinkage 
at follow-up 
Mechanical failure led 
to a higher than 
anticipated rate of 
target lesion 
revascularization; there 
is a second generation 
REVA which is under 
FIM 
 [36][37] Radio 
opaque; 
degradable in 
36 month; 
radial force 
comparable 
to a BMS 
IDEAL BDS: 
Poly(anhydride 
ester) (salicylic 
acid) 
FIM in 2011 Successful results 
in pig coronary 
arteries; in the 
case of human 
trials, reported 
absence of acute 
or chronic recoil; 
reduction in 
inflammation 
compared to 
BMS. 
Insufficient neointimal 
inhibition due to 
inadequate drug dosing 
and very quick elution 
of Sirolimus. This issue 
has been addressed in 
a second generation 
stent and is currently 
under evaluation 
human coronaries. 
 [38][39] Degradable in 
12 months; 
radial 
strength 
greater than 
BMS; 
resistant to 
gamma 
radiation 
Table1. Characteristics of Fully biodegradable Stents 
PLLA has good mechanical properties (E= 2,7-4,14GPa TS= 15-150MPa) which allow high 
scaffolding and high expansion ratio. It also has excellent resistance to corrosion and good 
biocompatibility due to a low complication rate and reduced in stent late loss. Degradation 
takes 12 to 24 months. It also shows less thrombogenesis in general and no stenosis has 
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been observed in a 3 year follow up with ABSORB. PLLA is also a really well known polymer 
as lots of studies have taken place for stent application and it is not expensive to 
manufacture.  
Therefore, PLLA has got all the properties necessary for the application and presents 
multiples clinical studies with good results. Furthermore, the only two certified fully 
biodegradable stents are made of PLLA. For all this reasons, PLLA would be the selected 
material. 
1.2.5. Surface functionalization 
Still, some drawbacks are related to the use of PLLA, the acidic products from its 
degradation gradually drop the pH in the implant zone, causing possible damage to local 
physiological activities and, therefore, inflammation [28].  But the main difficulty with PLLA is 
hydrophobicity and absence of cell recognition sites which decrease its capability of hosting 
cells. The bio functionalization of stents surface is an option to reach an appropriate cellular 
response. 
There are three different steps for bio functionalization. The first step is to create hydroxyl 
and carboxyl groups (OH and COOH) on our surface. In this project we did three different 
techniques for this step NaOH etching, ozone and plasma. Chemical surface composition is 
changed by means of covalent functionalization with diﬀerent molecules. First, the surface is 
pre activated by using sodium hydroxide which creates carboxyl groups due to the hydrolytic 
cleavage of the ester bonds of the PLLA substrate. Then the surface is activated and finally 
biomolecules are grafted using their primary amino-groups to create the covalent bond 
1.3. PLLA film fabrication 
The geometry makes the fabrication of stents rather expensive and complicated. Moreover, 
they are not suitable to be tested. Therefore, all testing and experiments will be done on 
films fabricated in the laboratory. This also enables us to work on different film fabrication 
methods that will allow better properties for our films. The dissolution and or the technique to 
obtain melted polymer, will be the same for films than for stents fabrication. 
In this part we focus on the fabrication of these PLLA films. There are many different ways of 
making these films, the most common is solvent casting [40] but we will also abroad 
extrusion and hot pressing techniques.  
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1.3.1. Solvent casting 
The oldest technology in plastic ﬁlms manufacturing, the continuous solvent cast process, 
was developed more than hundred years ago. In the years after 1950, new ﬁlm extrusion 
techniques of thermoplastic polymers became the dominant production method for plastic 
ﬁlms and the importance of solvent cast technology had declined. Nowadays, the solvent 
cast technology is becoming increasingly attractive for the production of ﬁlms with extremely 
high quality requirements. The advantages of this technology include uniform thickness 
distribution, maximum optical clarity and extremely low glare [41]. 
For the solvent casting procedure, the polymer must be soluble in a volatile solvent or water. 
A stable solution with a reasonable minimum solid content and viscosity should be formed. 
Formation of a homogeneous ﬁlm and release from the casting support must be possible. 
To provide these properties many process tricks are used such as co-solvent systems, 
dissolution at overpressure, use of special molecular weight distributions of polymers or co-
polymers, additives such as plasticizers or release agents [42]. 
The solid polymer in various geometrical shapes such as ﬂakes, granules chips or powder is 
dissolved in pure solvents or mixtures. Due to the large diﬀerence in viscosity, the geometry 
of the stirrer has to be carefully selected. Horizontal and vertical stirrers can be used, and 
the mixer elements may typically take the form of blades, anchors or spirals. The 
temperature must also stay constant as much as possible. Mechanical shear rate and 
temperature has to be carefully controlled. Indeed, it inﬂuences the quality of the dissolution 
process, the formation of particles, solvent evaporation and the degradation of polymer 
chains. The addition of plasticizer, additives, co-solvents and similar substances can be 
considered. 
The appearance of the film and the properties (elastic or rigid for example or viscosity of 
course) depend on the concentration of PLLA at the start of the mixing.  
Another possibility using this method is to try with different solvents [43]. It is also possible to 
use methylene chloride as solvent or a mixture of 50% methylene chloride and 50% 
acetonitrile instead of chloroform. 
1.3.2. Extrusion 
Another important technique when it comes to the fabrication of PLLA films is extrusion [44].  
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During ﬁlm extrusion of neat PLA the temperature was 160°C in the feeding zone, reached a 
maximum of 180°C, and was 175°C in the die. The ﬁlm is extruded vertically downward and 
drawn by chilled rolls. The thickness of the ﬁlm can be adjusted by controlling the speed. 
Also in our case, an extruder is a very expensive piece of machinery. Obviously to make 
PLLA films this technique would not be adapted to us. Therefore, another technique which is 
available to us is hot pressing. 
 
Figure7. Parallel twin screw extruder [45] 
1.3.3. Hot pressing 
Hot pressing is a technique based on melting the PLLA directly in an oven or furnace and 
then putting pressure on it and letting it cool down to harden into a film[46]. 
There are many parameters that can be changed with this technique to try and obtain the 
best film possible without any holes or bubbles. Mainly the temperature, the melting time in 
furnace and the pressure applied on the PLLA. Then, there are also different lubricants or 
plasticisers that can be added to the PLLA to enhance different properties such as 
mechanical properties.  Plasticisers heavily influence the glass transition temperature and 
crystallinity of a polymer. 
With citrate esters, a signiﬁcant improvement in elongation at break values can be achieved 
at the expense of tensile yield strength. Both hydrolytic degradability and enzymatic 
durability of the plasticized PLA compositions were inﬂuenced by plasticizer solubility, Tg 
and crystallinity [47]. 
Triacetin also called TAC is a plasticiser also used to blend with PLLA and improve its 
properties according to the concentration of TAC [48]. In this particular case, triacetin is used 
as a plasticiser on a composite made of PLLA and amylum. Amylum has variety of uses 
which also a potential useful polymer because of its inexpensive, renewability and 
biodegradability. In this study, the effect of addition of 1-10 % triacetin as external plasticizer 
on the 70/30 PLLA/amylum composite was investigated. 
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But in our case, forming copolymers such as these would be too complicated and time 
consuming. Also, the equipment at our disposal doesn’t enable us to try all these different 
techniques and combinations.  Therefore, we choose simple, easy and inexpensive 
techniques: solvent casting and hot pressing. 
1.4. Objectives 
The main objective is to obtain polymer films (PLLA) which present all properties necessary 
for cardiovascular applications and that can be bio functionalised.  
To do so we focus on the fabrication of PLLA films to then characterise them chemically, 
physically and mechanically to be able to use this material in the future as a totally 
biodegradable cardiovascular stent. 
To achieve this purpose, specific objectives have been planned: 
- Determine which processes enhance the best films for our application by concentrating 
initially on the film fabrication to obtain films with good surface properties (flat, transparent, 
homogeneous…) 
- Determine which surface treatments enhance carboxyl group creation and clean surfaces 
for cell adhesion 
- Thorough characterisation of the obtained films and surfaces before and after each 
treatment 
- Verify the degradation process and the change in properties of our chosen film to compare 
it to that of a real life stent 
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2. Materials and Methods 
2.1. Materials 
2.1.1. Poly lactic acid 
In this project we used the product PURASORB PL65 from PURAC Biomech BV.  
 
Figure8. Poly lactic acid (PLLA) 
 
Figure9. PLLA PL65 pellets 
PURASORB PL 65 is a GMP grade homopolymer of L-lactide. It is supplied in the form of 
white to light tan granules. PURASORB PL 65 is certificated for medical device applications 
and is suitable for all commonly used polymer processing techniques.  
Its weight average molar mass (Mw) is 1675000 g/mol. The others properties are 
summarised in the Figure 9 and 10.  
High molecular weight induces high scaffolding and better mechanical properties which is 
why we chose a high molecular weight PLLA. 
 
Figure10. PURASORB® PL data sheet 
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Figure11.PURASORB® PL 65 data sheet 
2.1.2. Cells  
The cells used were Human Umbilical Vein Endothelial Cells (HUVEC, Lonza). The cell 
culture assays were performed in an incubator at 37°C and 50% CO2. The HUVEC cell 
complete medium consisted of basal medium: the endothelial cells basal medium- 2 (EBM-
2), Foetal Bovine Serum (FBS) and complements (Lonza).the composition of the full medium 
is 90% basal medium EBM-2 and 10% serum FBS. 
Basal Medium  
Endothelial Basal Medium is a proprietary formulation containing essential and nonessential 
amino acids, vitamins, trace minerals, organic compounds and inorganic salts. It contains 
HEPES and sodium bicarbonate buffered and is free of hormones, growth factors or other 
proteins, antibiotics and antimycotics [49].  
Serum  
In cell culture, serum provides a wide variety of macromolecular proteins, low molecular 
weight nutrients, carrier proteins for water, insoluble components, and other compounds 
necessary for in vitro growth of cells, such as hormones and attachment factors. Serum also 
adds buffering capacity to the medium and binds or neutralizes toxic components [50]. 
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2.1.3. Commercial film 
We also characterised a commercial film, reference ME331050 given to us by Goodfellow 
Cambridge Limited, with the following properties: the molecular weight of PLLA is >150kDa 
and the typical level of crystallinity is 37%. However, the crystallinity of the moulded item will 
depend on the rate of cooling used. 
The tensile strength is 70 MPa, Young Modulus is 3.6 GPa. 
 
Figure12. Strip of commercial PLLA film 
2.2. Methods 
2.2.1. Films fabrication 
First of all, to prevent PLLA hydration, the material is sealed and maintained into the freezer 
at -15°C. The PLLA is contained in three bags, first one plastic with the pellets inside, 
second with the plastic bag containing the pellets to keep the temperature and third also 
plastic with other two inside it. Before starting the film fabrication process, it is important to 
get the PLLA at room temperature. To do so, we retrieve the bag from the freezer and leave 
it at room temperature completely sealed for 1h.  
Solvent casting 
We made solvent casting films with different concentrations, always. The different films were 
manufactured by means of solvent-casting method. First, PLA pellets were dissolved in 
chloroform at a 5%, 3,6% and 2,5% weight versus volume (w/v) ratio.  Specifically, 2,5 g 
PLLA pellets and a variable chloroform amount: 50 ml, 70 ml and 100 ml. PLLA and 
chloroform were mixed in a beaker with aluminium foil covering the top of the beaker first 
and then three strips of Para film around and across the top of the beaker over the top of the 
aluminium foil to prevent chloroform evaporation. The dissolution takes approximately two 
days on an orbital shaker, 150 rpm, at room temperature.. The paste is spread on a Teflon 
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sheet in a glass Tupperware saturated with chloroform until complete chloroform 
evaporation, around 3 days.  
The entire solvent casting film preparation process must take place under a fume hood 
because of the emanation of chloroform. 
 
Figure13. Laboratory fume hood, Quimipol Spain (rotator with solvent casting films on 
the right)  
Once the films are formed, they are unstuck from the glass container with plastic tweezers to 
avoid damaging them. Then, the films are cleaned with MilliQ water and ethanol and dried. 
The films are stored each in separate clean plastic bags. Finally, they are sealed, marked 
with the name and date of the film to be able to recognise them when doing the testing and 
ready for experiments and characterisation.  
 
Figure14. Solvent casting film 70 ml of chloroform  
 Methylene chloride, dichloromethane, was also used as a solvent to dissolve PLLA pellets 
instead of chloroform. The same protocol  was used as for chloroform solvent and the 
concentrations studied were the same a solution with 70ml (concentration 3,6% 
weight/solvent) of solvent and one with 100ml (concentration 2,5% weight/solvent) of 
solvent.  
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Hot pressing 
The technique allows obtaining PLLA films without the use of a solvent. The PLLA pellets 
are melted at 240°C on a small Teflon plate of small plates of approximately 8x8 cm2 size.  
 
Figure15. Laboratory oven, Heraeus  
0,9 g of PLLA was placed on a Teflon sheet and covered with another Teflon sheet. This 
assembly was placed inside the oven, Figure 16,  at 240°C with two 20 kg metal blocks on 
top, already warmed at the oven temperature,  during 1h.  
After one hour, the melted PLLA was left to cool down, at least overnight, still between the 
two Teflon sheets at room temperature with the two metal blocks on top.  
The other film with this technique was obtained by melting the PLLA pellets placed on a 
Teflon sheet in the oven for 30 min at 240°C and then placing the other Teflon sheet and the 
two metal blocks (already at oven temperature) over the top in the oven. The structure was 
left in the oven for another 40 min before being taken out and left to cool down at room 
temperature overnight. 
With hot pressing, there are many conditions that can vary such as temperature in the oven, 
time in the oven, weight of PLLA, pressure during melting or after melting, pressure in or 
outside the oven and so on. We tried many different ones but the previous protocol is the 
one that gave us films with less holes and homogenous thickness 
We also tried making films with a commercial hot-press previously fabricated in the Dept. 
Enginyeria Química of the U.P.C. The hot press consists of two separated metal plates 
connected to electrical resistances in order to heat the metal plates to a controlled 
temperature. We placed our PLLA pellets between two sheets of Teflon, put the Teflon on 
top of the bottom metal plate and applied the pressure with the top metal plate thanks to a 
wheel. The pressure was applied during 5 min at 205°C. Then we release the pressure 
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thanks to the wheel again and let the Teflon cool down before retrieving the film. Two 
different films were obtained bothwith the same conditions.  
 
Figure16. Hot pressing machine 
2.2.2. Heat treatments 
Pellets pre-treatment under argon 
Solvent casting film fabrication could still be enhanced, by doing a thermal treatment under 
argon atmosphere directly on the PLLA pellets before mixing them with the solvent. The 
thermal treatment helps to preserve the high molecular weight and high cristallinity thanks to 
the dehydration on the PLLA pellets [51].  
PLLA pellets were placed in a beaker and then put in a sort of glass bowl with a glass lid 
with a gap allowing two tubes to go through.  
The tubes were made of Teflon to make sure they didn’t melt in the oven. One tube was 
linked to the argon and the other tube for air to leave the glass bowl. The glass bowl was 
placed in the oven at 80°C with argon flowing through it for 2h.  
Then the film fabrication process was the same as previously with the PLLA pellets and also 
same with cleaning, bagging and the use of the desiccator for 12h.  
 
Figure17. Glass bowl with lid and tubes for argon heat treatment at 80°C 
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Films post-treatment 
We also did a post treatment on the fabricated films which consisted in annealing them in the 
oven at 80°C for 14h between two Teflon sheets to keep the shape and the flatness of the 
films. We did this in order to evaporate residual chloroform which makes our films toxic for 
the human body and also to increase cristallinity as well as mechanical properties.  
2.2.3. Surface treatments 
Different surface treatments where performed to the different films in order to activate and 
create hydroxyl and carboxyl groups. It is an intermediate stage before functionalization of 
the surfaces. NaOH, plasma and ozone create COOH and OH groups on our surface.  
Moreover, the treatments can affect polymer crystallinity, molecular weight, mechanical 
properties, and degradation, among others. 
For NaOH, the hydroxide anion hydrolyses the ester groups resulting in the breaking of the 
polymer chain and the formation of carboxylic acid and hydroxyl groups on the termini of the 
two new chains [74]. 
With plasma, the polymer is exposed to non-thermal plasma sustained in O2, air, N2 or NH3, 
oxygen- and nitrogen containing functionalities are, respectively, introduced onto the 
polymer surface. These polar hydrophilic groups are formed due to the interaction of 
chemically active species generated by the gas discharge plasma with different groups of 
polymer molecules. 
Ozone activation can create sites that possess high chemical activity on a material’s surface, 
and a modiﬁcation or further graft can thus be carried out. On the surface of polymers, the 
ozone oxidation can produce peroxides and hydro peroxides with free radicals and the 
following immobilization of functional molecules can be performed [76]. 
In this project, functionalization will not be performed, but the effect of surface treatments, 
basic etching, ozone and plasma radiation, on the polymer properties will be studied.  
NaOH etching 
The NaOH etching treatment was realised by immersing the samples in a 1M NaOH solution 
during different amounts of time: 1 h, 3 h and 5 h on the different films series.  
The NaOH solution was prepared in a beaker by diluting 4 g NaOH (MW=40, Panreac) 
granules in 100 ml of distilled water. After treatment, a thorough cleaning was performed 
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during 30 min with ultrapure water in an ultrasonic bath. This step was performed twice using 
fresh distilled water. 
O2 plasma radiation  
O2 plasma treatment starts by placing the samples in a vacuum chamber. Oxygen is then 
inserted at low pressure and a high voltage is applied in the chamber resulting in oxygen 
plasma. The surface is ion bombarded and atoms and molecules are removed under the 
high energy of the ions. 
 
Figure18. Plasma activation process [60] 
Plasma treatment was performed in a Plasma Cleaner, Sterilizer PDC-002 (Harrick Scientific 
Corporation, USA) with an oxygen gas at 0,5 bar subjected to high frequency voltage during 
5 min in order to ionize the gas at low pressure (Figure27). Before applying the discharge, 
vacuum has been performed during 5 min. The O2 plasma radiation was applied for 30 s, 2 
min and 5 min on the different samples. 
 
Figure19.  Image of the Plasma Cleaner Sterilizer PDC-002 
Ozone radiation 
UV-Ozone cleaners radiate the active specie O3 that is more reactive than O2 from plasma 
treatment [61].  
Atomic oxygen is simultaneously generated when molecular oxygen is dissociated by 184.9 
nm and ozone by 253.7 nm UV. The 253.7 nm UV radiation is absorbed by most 
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hydrocarbons and also by ozone. The products of this excitation of contaminant molecules 
react with atomic oxygen to form simpler, volatile molecules that desorbs from the surface. 
Therefore, when both UV wavelengths are present atomic oxygen is continuously generated 
whereas ozone is continually formed and destroyed. 
The ozone cleaner used is a UVO Cleaner 42 (JeLight Company Inc., Irvine, California, 
USA)(figure28). The samples are placed into the machine for 20 min, 40 min, 1 h and 2 h 
treatment on the different films. The device simply works on an on-off switch.  
 
Figure20. Laboratory Ozone cleaner UVO cleaner 42, United States 
2.2.4. Surface characterisation 
Scanning Electron Microscopy (SEM)  
Scanning electron microscopy is employed for the structural and morphological 
characterisation of the samples .It allows a surface characterisation with high resolution and 
can reach a magnification of 100.000X. It has a larger depth of field in comparison to light 
microscope.  SEM is essentially used to obtain information about surface morphology and 
repartition of different phases on the surface and their composition [52].  
Images obtained by electronic microscopy are formed by electrons. The principle of 
scanning electron microscopy is based on the interactions electrons-material.  
 
Figure21. Laboratory SEM and EDS, Zeiss Neon 40 
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Samples have to be conductor to avoid accumulation of charges. The measurements were 
performed with the scanning electron microscope SEM ZEISS NEON 40. The samples were 
hit with an acceleration voltage also called Extra High Tension (EHT) of 5 kV, an aperture 
size of 30 µm and a working distance (WD) of 6 mm. All photos were taken with a 
magnification of 500.  
Energy dispersive spectrometry (EDS)  
The SEM also has a system of X-Ray micro-analysis called Energy dispersive spectrometry 
(EDS). It informs us about the chemical composition of the surface of the sample. We can 
find out about the presence of particular chemical elements, their amount and their 
repartition in our sample. We used the same films as the SEM. 
White-light interferometer  
White light interferometer is a non-contact optical profiler providing 3-D surface 
measurements. It gives information about the surface topography. It can be used for the 
characterisation of both smooth and rough surfaces thanks to two modes. With the phase- 
shifting interferometry (PSI) mode it can be measured smooth surfaces and small steps, 
while vertical-scanning interferometry (VSI) mode allows rough surface measuring and shifts 
up to several millimetres high. 
 
Figure22. White light interferometer [53] 
The measurements were realised with an interferometer microscope (WYKO Surface 
Profilers) and the data was exploited with the associated software, WYKO Vision32.  For 
each type of sample, we performed 9 measurements at full resolution. We proceeded to 
Vertical Scanning Microscopy (VSI) with the following parameters:  
- Objective of magnification 50X  
- Light objective: 2X 
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Figure23. Laboratory interferometer, Veeco Wyko NT 9300, United States 
To characterize the surface roughness of the samples, we determined the following surface 
parameters: 
Sa is the average arithmetic roughness. It’s the same as Ra but in three dimensions. It is the 
arithmetic mean of the absolute values of the surface departures from the mean plane.   
   
 
  
∑ ∑         
 
   
 
     (Eq 1) 
Sz is the value of the difference between the maximum peak and the maximum valley. 
                  (Eq 2) 
Sm is the mean spacing at mean line. This parameter is defined as the mean spacing 
between profile peaks at the mean line. The profile peak is the highest point of the profile 
between upwards and downwards crossing the mean line. 
   
 
  
   (Eq 3) 
SAreaIndex is the equation between the real area and the nominal area and indicates how 
flat the surface is. 
       
                
                 
 (Eq 4) 
Contact angle 
The contact angle provides information about interactions between a solid (the sample’s 
surface) and a known liquid. It characterises the resulting interfacial tension, by calculating 
the surface energy and by studying the wettability of the surface [54] 
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Wettability is the capacity of a liquid to spread on a solid substrate. This is related to 
molecular interactions occurring on their respective surfaces. The system created tends to 
equilibrate depending on the surface tension existing between the liquid and the solid.  
Wettability is related to the contact angle which enables to quantify it .The contact-angle θ is 
defined as the angle between the surface’s tangent and the tangent to the drop’s profile at 
the triple point where vapour, liquid and solid joins (Figure 25).   
The measurement of the contact-angle consists in depositing a drop of a known liquid on the 
sample’s surface and measuring θ. The more swelled the drop is, the more hydrophobic it is 
(high θ). If there is much affinity between the surface and the liquid, the drop can spread and 
it becomes difficult to measure any contact angle. It is said that there is a high wettability and 
that the surface is hydrophilic [55]. 
The contact-angle characterizes the interfacial tension between the solid and a liquid drop. It 
represents an equilibrium state between the three interfaces solid/liquid (ɣsl) liquid/vapor 
(γlv) and solid/vapor (γsv). It can be determined by the Young-Laplace equation [54]: 
                    (Eq 5) 
 
Figure24. Contact-angle θ, surface free energy of the solid (ɣsv), surface tension of the 
liquid (ɣlv) and interfacial free energy between the liquid and the solid (ɣsl) related by 
Young’s equation [56] 
But only two of the four variables can be measured in the previous equation by Young. This 
led to different approaches being proposed to solve Young’s equation [54]:  
a) Neumann’s approach requires the measurement of the contact-angle with only one liquid. 
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b) Polar-dispersion approach / Owens and Wendt approach. 
 c) Electron Donor – Electron Acceptor Approach / Acid-Base / Good van Oss approach. 
 In this project we used the Owens and Wendt approach to calculate the surface tension. 
The polar-dispersion approach introduced by Fowkes suggested dividing the surface tension 
as the sum of two components: a dispersive one due to Van der Waals or London forces and 
a polar one mainly due to hydrogen bonding. This approach implies to carry out 
measurements for two different liquids.   
The resulting Owens-Wendt adaptation of Young’s equation is given by [57]:  
                     
      
             
      
      (Eq 6) 
Where:     
 is the dispersive part of liquid surface tension 
   
 is the dispersive part of the solid surface tension 
   
 
is the polar part of liquid surface tension and  
   
 
is the polar part of the solid surface tension 
The measurements were carried out with a contact angle goniometer dataphysics OCA15  
(Germany) and analysed with the software SCA 20. Contact angles were obtained by the 
sessile drop method, static method consisting in the deposition of a liquid drop of 3ul at room 
temperature generated by a micrometric syringe on the sample surface. 
 
Figure25. Drop deposed using sessile drop method 
Every contact-angle has been measured with two different liquids: ultra-pure distilled water, 
a polar liquid and diiodomethane CH2I2, a non-polar one. The surface-free energy was 
calculated using the following data provided by Ström et al [58]. 
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Liquid     [mJ/m
2
]    
  [mJ/m
2
]    
 
 [mJ/m
2
] 
Water (Milli-Q) 72,8 21,8 51,0 
Diiodomethane 50,8 50,8 0,0 
Table2. Surface free energy data 
 
Figure26. Laboratory contact angle, dataphysics OCA 15, Germany 
Gel permeation chromatography (GPC) 
Gel permeation chromatography (GPC) has become the most widely used technique for 
analysing polymer samples in order to determine their molecular weights and weight 
distributions.  
The data that produced the chromatogram is then compared to a calibration that shows the 
elution behaviour of a series of polymers for which the molecular weight is known. This 
allows the molecular weight distribution of the sample to be calculated. 
GPC analyses have been carried out in an Agilent Infinity 1260 chromatograph, equipped 
with degasser, pump, auto sampler, UV-vis and RI detector. Separation was performed with 
a Jordi Associates mixed bed fluorinated column (permeation range: 100 - 10·10^6 Dalton). 
Mobile phase was 0,02 mol/L NaTFA in HFIP, running at 1 mL/min. 100 microliter samples 
about 0,1% concentration were injected. Detection was conducted with UV-vis-detector. 
Monodisperse PMMA samples from Sigma and Agilent were used for calibration. 
Differential Scanning Calorimetry (DSC) 
Differential Scanning Calorimetry (DSC) measures exchange heat associated with materials 
phase transitions as a function of temperature. The technique provides qualitative and 
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quantitative information about physical and chemical changes that involve endothermic or 
exothermic processes or changes in heat capacity using minimal amounts of sample.  
 
Figure27. Example of DSC graph 
DSC measurements were carried out on a TA Instruments DSC 2920.  
 The samples were heated from 30°C to 200°C followed by cooling back to 30°C at a rate of 
10°C per minute. The glass transition temperature (Tg), crystallisation temperature (Tc), 
melting temperature (Tm), heat of melting (ΔHm), and heat of crystallisation (ΔHc) were 
measured from these heat ﬂow curves.  
The heat of melting, ΔHm, and the melting temperature, Tm, were recorded during the first 
cycle in order to determine the crystallinity, Xc. The melting temperature was defined as the 
minimum of the melting peak. The heat of meltng is defined as the area of the melting peak. 
The degree of crystallinity was determined according to following equation where (ΔHm) 
100% = 93 J/g is the heat of melting for 100% crystalline PLLA. 
To calculate cristallinity percentage, we use the following equation [59]: 
 (Eq 7) 
 
Figure28. Laboratory DSC, TA Instruments DSC 2920, United States 
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Mechanical properties: tensile test 
A tensile test consists of submitting a normalised sample to axial tension traction. Tensile 
testing is one of the most fundamental tests for engineering, and provides valuable 
information about a material and its associated properties. These properties can be used for 
design and analysis of engineering structures, and for developing new materials that better 
suit a specified use. From the resulting stress strain curves we can deduce the following 
parameters among others: 
a) Young modulus or elastic modulus: E in GPa. Slope of OP line. 
b) Yield strength: Rp0,2 in MPa. Sy 
c) Ultimate tensile strength: UTS in Pa. Su 
d) Strain: A in %. ƐF 
The results are shown as a stress strain curve. There are two main zones, elastic domain, 
small deformation and the plastic domain after Rp0, 2 with higher deformation. 
 
Figure29. Example of stress strain curve [62] 
To cut the films we used standard D 6287 – 98 [77] 
 
Figure30. Dual blade shear cutter 
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Figure31. Laboratory tensile test machine, DY 34 Adamel Lhomorgy, France 
The speed of grip separation and testing was the same for all the samples 15mm/min. All 
tests were done using the same tensile testing head of 100N. Grips were made of carbon 
fibre to avoid slippage as much as possible and all tensile tests were done according to 
standard D 882 – 02 [78]. 
2.2.5. Biological characterisation: indirect cytotoxicity test 
To evaluate the citotoxicity of the fabricated films we did an indirect cytotoxicity test, the 
lactate dehydrogenase (LDH) test (Roche) [79].  
For the test we cut the selected films in 6cm² discs and placed them in separate wells in well 
plate (Nunc) of 48. All the samples were incubated with completed cell medium during three 
days in the incubator.  
The following step is, after having checked by optical microscopy that the cultured cells have 
proliferated and attached to the TCPS flask, we detached the cells by trypsinization.  
 Trypsinization  
- The medium is first thrown away and the cells are rinsed with PBS, a physiological buffer 
before proceeding to the cell detachment. We use 1 ml trypsin (TrypRE Express), an 
enzyme that clears protein for cell-detaching them from the support after immersion during 
2-3 min at 37°C. 
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- Once the cells have been trypsinizated, we add 10 ml of complete medium  to neutralise 
the action of trypsin. We take 10 ml of the mixture (Trypsin + medium + cells) and put it in 
centrifuge for five minutes at about 1700 rpm.  
- After centrifuge, the medium (basal + trypsin) is thrown away and the cells accumulated at 
the bottom of the centrifuged tube are mixed with new complete medium. 
Calculation of the number of cells  
The cells that were collected are counted with the Neubauer method.  
First we take 10 µl of the medium full of cells and deposit it on the central area of the thick 
crystal slide (30x70 mm2 and 4 mm thickness). We cover it with a thin glass cover. The 
central part of the glass contains the counting grid 3mm x 3mm in size. Using an optical 
microscope we then count the number of cells in the first square including two axes. The 
counting is repeated for each square of the counting grid. The number of cells is given by the 
means of the four previous squares.  
To obtain the final cell concentration (cells/ ml) in the initial flask, we just multiply the 
measured number of cells by 10 000. 
The result represents the number of cells times 10 000 contained in 1 ml. This value is used 
to calculate the volumes corresponding to the different required cell quantities. 
 
Figure32. A) Neubauer hemocytometer  B) Cell counting procedure 
Then in a well plate of 96 wells we put 15 000 cells per well thanks to the solution we just 
made. We calculate the amount of this solution we need to put 15000 cells per well and add 
full cell medium to it to fill all the wells with 200 µl.  
The following day we evacuated the entire medium in the wells and added instead different 
concentration of the medium that has been in contact with our films for three days.  
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The medium in contact with the PLLA films is filtrated using a syringe and corresponds to the 
full extract (approximately 3ml). 
 The different concentrations that should be used are specified in the standard. Each 
concentration is tried three times for each film. The concentrations are calculated from the 
pure extract which was in contact with the films. With regard to the standard, the following 
table3 shows the different concentrations we used from the pure extract completed with full 
cell medium.  
Pure extract: 200ul E 
Pure Extract /2: 100ul E+100ul M 
Pure Extract /10: 20ul E+180uL M 
Pure Extract /100: 20 ul (1/10)+180ul M 
Pure Extract /1000: 20uL  (1/100)+180uL M 
Control-: 200uL M 
BLANC: 200uL M 
Table3. Organisation of samples for cytotoxicity test 
E: medium in contact with the film (pure extract) (3mL) 
M: complete medium 
1/10: 10% pure extract and 90% complete medium 
1/100: 10% extract 1/10 and 90% complete medium 
1/1000: 10%extract 1/100 and 90% complete medium 
Control: cells with normal medium 
Blanc: only medium no cells 
After cell adhesion, the medium is emptied; PBS is added in each well to remove possible 
dead cells, and then flushed. We finally kill the attached cells using M-PER, a mammalian 
extraction reagent in order to free the LDH enzyme from the cytoplasm which will be 
measured to quantify the adhered cells. The cells are then placed in a freezer at -80°C. The 
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high cold allows keeping the conditions of LDH activity at the moment of defrosting when the 
measurement is carried out [63]. 
 
Figure33. Telstar AV 30/70 cell hood, Spain 
LDH test 
To quantify the number of adhered cells it has been used an indirect technique, the  LDH 
test which is a biochemical technique of detection of lactate deshydrogenase. LDH is a 
stable enzyme contained in the cytoplasm of cells. When one proceeds to their lysis, the 
plasma membrane is damaged and LDH is released in the medium: the cell- free 
supernatant. The amount of LDH detected is correlated to the proportion of damaged cells. 
The more LDH is detected the more cells were adhered to the samples.  
To measure its quantity, it was a prepared kit of reagents (the Cytotoxicity Detection Kit 
PLUS provided by Roche Diagnostic GmbH,Germany) leading to a mixture reaction which, 
when mixed with the LDH-containing medium, colours itself according to the presence and 
amount of the enzyme[64]. 
Reactions occurring:   
1) NAD+ is reduced to NADH/H+ by the LDH-catalysed conversion of lactate to 
pyruvate. 
2) The catalyst (diaphorase) transfers H/H+ of NADH/H+ to the tetrazolium salt INT 
which is reduced to formazan. This leads to colour change from pale yellow to red 
[65].   
The quantity of LDH is then measured by colorimetry knowing that the enzyme reduces the 
INT into a red colour formazan. Formazan shows maximum of absorbance at 492 nm. We 
thus deduce the quantity of LDH and further the quantity of cells. 
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The mixture reaction contains: a catalyst: diaphorase/ NAD+, and a dye solution containing 
the salt iodonitrotetrazolium chloride (INT) and sodium lactate.   
We carried out this test on nine different films in three different boxes of 96 wells (one box 
with just one film, the two others with four films each). 
The percentage of living cells is calculated thanks to this equation: 
%living cells= 
           
      
  (Eq 8) where V is the number of cells in the well, Vb is the number 
of cells in the well Blanc and Vc is the number of cells in the control well. 
2.3. Polymer degradability 
Accelerated degradability test was performed in order to have knowledge about the 
degradation of the modified films compared to commercial biodegradable PLLA films and to 
a totally biodegradable stent.  There are at least two ways to accelerate the hydrolysis 
process of degradation: (1) raising the temperature of the degradation medium or (2) adding 
hydroxyl ions  by dipping the samples in a solution of NaOH at a chosen concentration 
[66][67]. 
 The latter method seems to be more suitable due to the incubation temperature of 37°C, 
close that of the body, avoiding the change in mechanical properties of PLLA specimens. 
Each sample weighed between 15mg and 20mg initially and four samples were cut per film. 
 To tests the effect of degradation, the films were characterised through DSC and the weight 
loss for each sample was also calculated using the following equation:  
% mass loss = 100 x (mi –mt)/mi  (Eq 9) 
Where mi is the initial weight of the simple and mt is the weight of the sample after 
degradation. Before degradation tests, all the specimens must be weighed thanks to 
precision scales (three decimals). 
All the test lasts one week, but four measurements where performed at different times. All 
samples where thoroughly cleaned twice in distilled water in an ultrasonic bath prior to 
characterization and dried first with paper then in a vacuum oven at 48°C for two hours [68].  
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3. Results and discussion 
3.1. Film selection 
The first step was to fabricate films by solvent casting and hot-pressing and to characterize 
these films in order to choose which protocol provides us the materials with the more 
suitable properties for stent implants.  
So for this preliminary study we focused mainly on 4 parameters:  
 visual aspect which can give us information on the mechanical properties of the 
fabricated films,  
 roughness which has an impact on platelet adhesion,  
 wettability which gives us information on the biocompatibility and the potential cellular 
response  
 cristallinity which gives us information on the possible structural changes due to 
fabrication process, the mechanical properties and on the degradability of the 
material. 
These parameters were characterized by contact angle, DSC and white-light interferometry. 
All the films obtained are named based on the fabrication technique, the date and for solvent 
casting films the amount of chloroform. The amount of PLLA never varied for solvent casting 
films (2,5 g) and also for hot pressing films (0,9 g). 
The films fabricated and characterized in this part are summarised in the following table4. 
Name Fabrication process 
Com Commercial film 
SC100 Solvent casting 2,5 g 
PLLA 100 ml 
chloroform (2,5% w/v) 
SC70 Solvent casting 2,5 g 
PLLA 70 ml chloroform 
(3,6% w/v) 
SC50 Solvent casting 2,5 g 
PLLA 50 ml chloroform 
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(5% w/v) 
SC100 Dichloro Solvent casting 2,5 g 
PLLA 100 ml 
dichloromethane (2,5% 
w/v) 
SC70 Dichloro Solvent casting 2,5 g 
PLLA 70 ml 
dichloromethane (3,6% 
w/v) 
Artisanal HP1 Hot pressing 0,9 g 
PLLA 240°C 1h with 
pressure in oven 
Artisanal HP2 Hot pressing 0,9 g 
PLLA 240°C without 
pressure 30min then 
with pressure 40min in 
oven 
Conventional HP Hot pressing 0,9 g 
PLLA with hot press 
Table4. Obtained film names 
3.1.1. Visual aspect 
Solvent casting 
As expected SC50 films were the most viscous leading to a smaller surface but larger 
thickness due to the high concentration. Also we had major difficulties pouring the mix from 
the beaker into the Tupperware. As the concentration decreases, the viscosity reduces and 
then, SC100 films were easily poured and spread in the glass Tupperware. But both series 
had: many small and some large bubbles, most likely due to air trapped in the film during 
dissolution or due to evaporation of chloroform.  
SC70 films showed a good surface aspect with fewer bubbles, homogeneous and easier to 
pour. Also, there is less chloroform used during dissolution than SC100 films so there should 
be less of a risk of residual chloroform trapped in our films which would be toxic for cells. 
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Figure34. SC100 right SC70 left 
For SC Dichloro films, the obtained films presented many small bubbles and transparency 
was nowhere near as good as the films we made with chloroform.  Then, this technique was 
not considered as a candidate for further assays. 
 
Figure35. SC70 Dichloro 
Hot pressing 
Different trials were performed in order to obtain reproducible films by changing protocol 
parameters such as temperature and time of the thermal treatment, pressure in the oven 
during melting with 20kg blocks or even disposition of the pellets on the Teflon plates but 
most times our films were in poor condition. There were many holes, grooves in some cases, 
thickness was not homogenous, surface was not really flat and films had dirty particles 
incrusted inside. Finally, Artisanal HP1 and Artisanal HP2were obtained with good visual 
aspect but reproducibility was not achieved.  Then, this technique was not considered as a 
candidate for further assays. 
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Figure36. Artisanal HP films  
 
It was also tried to make films with a hot press and two Conventional HP films were obtained 
but the results were not satisfying. They both presented many holes and one even had a 
groove down the middle. Then, this technique was not considered as a candidate for further 
assays. But the films were characterised for comparison purposes with solvent casting 
technique.  
 
Figure37.Conventional HP films made with a hot-press 
3.1.2. DSC 
Differential scanning calorimetry technique allows to detect phase transitions and to obtain 
the cristallinity of all the selected films. For our application, biodegradable cardiovascular 
stents, it is necessary not to lose cristallinity from raw PLLA pellets during films fabrication 
and treatments to improve mechanical properties [69] [70]. 
All the DSC measures started with samples ranging between 10 and 20 mg obtained from 
film cut. Temperature was set at ~35°C then the temperature rises up to 200°C at 10°C/min. 
During the experiment, there is a 1 bar nitrogen flow passing through the system to avoid 
oxidative degradation. 
 
 ΔHc (J/g) ±SD ΔHf (J/g) ±SD % Cristallinity ±SD 
PLLA PL65 pellet 50,13±0 0±0 53,9±0 
SC100  22,68±3,52 0,22±0,37 24,15±3,65 
SC70  21,19±3,81 1,08±1,70 21,62±2,27 
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SC50  20,64±0,69 0±0 22,1±2,74 
SC100 Dichloro 23,74±1,52 11,15±5,79 13,53±7,87 
SC70 Dichloro 26,83±0 0±0 28,85±0 
Artisanal HP 36,55±2,75 0±0 39,29±2,96 
Conventional HP 19,18±3,88 1,45±1,05 19,07±3,04 
Com 32,7±0 0±0 35,16±0 
Table5. % Cristallinity results obtained by DSC 
 
Figure38. DSC curve for PLLA PL65 pellet (15,52 mg) 
  
Figure39. Percentage cristallinity obtained by DSC 
Artisanal HP films have much higher percentage than SC films indicating a lower 
degradation of the raw material. Unexpected values were obtained with conventional HP 
films fabricated with the hot press since they have similar percentages of cristallinity as SC 
series.  Overall SC100 have a slightly higher percentage of cristallinity than SC70 and SC50 
series with chloroform as solvent. The SC Dichloro films showed a lower cristallinity but a 
very high dispersion between the different obtained samples. That’s the reason why these 
series were not considered as a candidate for films fabrication in further assays.  
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Figure40. DSC curve for SC100 Dichloro1 (11,05mg) 
The values obtained for the commercial film were similar to the provided by the manufacturer 
(37%). 
3.1.3. White-light interferometry 
The roughness for solvent casting films series was measured at two sides: 1) the bottom 
part, in contact with the glass during film fabrication ; 2) the top part corresponding to the 
upper part  not in contact with the glass.  If the film was in contact with the glass or not, 
made a difference in terms of roughness.  
For films made by hot pressing, the conditions for both surfaces were the same; therefore it 
was only measured one side for each of these films. Also it was measured the roughness of 
the commercial strip of PLLA. For each film, we made 9 measures with objective of 
magnification 50X, light objective 2X which is the highest magnification possible and is best 
for rough samples.  
 Sa ±SD(nm) Sz ±SD (nm) 
 Top Bottom Top Bottom 
SC100 680,49±153,26 246,56±131,88 5636,53±957,15 2374,41±907,83 
SC70 218,37±178,39 115,10±55,91 2305,06±1384,82 1485,89±200,48 
SC50 101,92±20,63 115,05±39,60 1497,01±298,71 1915,48±287,61 
SC100 Dichloro 181,93±60,05 87,42±34,47 2062,20±96,85 1537,50±413,29 
SC70 Dichloro 363,99±264,86 79,95±18,21 2770,98±1442,36 1245,26±634,65 
Artisanal HP 329,88±81,87 4141,04±1075,10 
Conventional HP 226,99±23,08 3075,02±507,26 
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Com 60,48±24,03 2196,55±1207,91 
Table6. Roughness parameters obtained by interferometry for the different films. 
Mean values ± standard deviation  
 
 Sm ±SD(mm3/m2) SAreaIndex ±SD 
 Top Bottom Top Bottom 
SC100 28±15,63 41±65,82 1,05±0,02 1,03±0,03 
SC70 11,77±4,20 13±7,28 1,01±0,00 1,01±0,01 
SC50 10±3,09 7,5±1,64 1,02±0,01 1,05±0,02 
SC100 Dichloro 12±6,58  1,01±0,00  
SC70 Dichloro 22,9±16,6 5,78±2,68 1,02±0,01 1,00±0,00 
Artisanal HP 18,66±5,19 1,17±0,06 
Conventional HP 16,88±3,37 1,12±0,03 
Com 13,33±8,94 1,02±0,01 
Table7. Roughness parameters obtained by interferometry for the different films. 
Mean values ± standard deviation 
  
Figure41.  Mean roughness value, Sa, obtained by interferometry for the different 
films. Measures were performed at the top of the film. Mean ± standard deviation 
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Figure42. Mean roughness value, Sa, (nm) obtained by interferometry for the different 
films. Measures were performed at the bottom of the film. Mean ± standard deviation  
As expected, the roughness of the bottom part of the solvent casting films is lower than the 
top part and also lower than the HP films. The roughness of the top part of SC100 films is 
higher than the hot pressing. The top parts of solvent casting films have many bubbles due 
to chloroform evaporation. Solvent casting procedure obtained the lowest mean roughness 
compared to hot pressing fabrication  
For the SC100 Dichloro2 film, it was not possible to measure since the bottom side was too 
opaque and the film did not reflect the light of the interferometer. The roughness of the 
SCDichloro films is very similar to the SC70 and SC50 films. These three types of film show 
the lowest Sa roughness values. 
Sm and Sz values seem to follow the same trend as Sa values. The lowest are for SC70, 
SC50 and SC Dichloro films. SAreaIndex stays the same for all films, except the hot 
pressing films where the value is slightly higher. 
3.1.4. Contact angle 
The wettability for the solvent casting films was also measured at the bottom and at the top 
sides of the film. We did 10 measures per film with water and diiodomethane Ch2I2 and 
reported the average and the standard deviation. 
 CA(°) water ±SD CA(°) diiodomethane ±SD 
 Top Bottom Top Bottom 
SC100  80,5±3,9 79,6±4,4 25,4±3,6 34,3±2,5 
SC70  80,4±2,9 82,2±1,5 22,0±1,5 32,5±3,8 
SC50  78,7±1,7 83,1±1,8 37,3±4,0 35,1±7,3 
SC100 Dichloro 78,4±6,1 79,5±1,9 35,8±2,2 42,1±1, 
SC70 Dichloro  79,04±1,65 78,52±1,82 32,14±1,4 39,98±2,31 
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Artisanal HP 88,2±4,8 48±2,1 
Conventional HP 89,2±2,6 49,44±2,3 
Com 72,0±2,3 35,0±2,9 
Table8. Contact angle with water and diiodomethane of the fabricated films. Mean ± 
standard deviation 
 
Figure42. Contact angle with water of the fabricated films. Mean ± standard deviation  
 
Figure43. Contact angle with diiodomethane of the fabricated films. Mean ± standard 
deviation 
HP films have a higher contact angle value than SC films and also the commercial film, so 
they are hydrophobic. Probably, the higher roughness leads to a higher contact angle. No 
relevant differences in contact angle are found between artisanal or conventional HP films 
independently if it is measured with water or diiodomethane.  
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Contact angle measures between the top and the bottom side of the SC films are virtually 
the same. In most cases there is little variation. SC Dichloro films have very similar contact 
angle to other SC films whatever the concentration. 
3.1.5. Film selection conclusion 
Overall, the films showing the best properties were SC70 films. In terms of fabrication 
aspects of those films have fewer bubbles than SC100 films, easier to pour and more 
homogeneous than HP films. HP films have many holes and grooves inducing higher 
roughness whether it’s with artisanal or conventional procedures. Reproducibility with 
artisanal HP films is also a very important issue as in it was very obtain films with the same 
properties even though we used the same protocol. Cristallinity is higher with artisanal HP 
films than SC films but conventional HP films presented the lower values. Contact angle is 
also much higher with HP films than with SC films probably due to the higher roughness. 
Then, from that results, it was found that hot pressing was not enough reproducible and 
homogeneous for our purposes, therefore we focused on solvent casting technique. 
Cristallinity and roughness in general was the best for SC50 and SC70 films compared to 
SC100 and SC Dichloro films. Also SC Dichloro films weren’t as transparent as SC films 
which caused problems during interferometry testing. SC Dichloro films also had very 
heterogeneous results concerning cristallinity.  
Taking all this into considering, we decided the best films to pursue our experimentation 
were SC70 films.   
3.2. Thermal treatments 
With SC70 films, we then made different heat treatments in order to improve the properties 
of the material and to eliminate the possible solvents residues. All the films fabricated and 
characterised in this section are summarised in the following table11. 
Name Fabrication process Heat treatment 
Com Commercial film  
SC70 Solvent casting 2,5g 
PLLA 70ml chloroform 
 
SC70 HTAR Solvent casting AFTER 
pellets treatment  2,5g 
PLLA 70ml chloroform 
Pellets heated at 80°C 
under argon 
atmosphere 2h pre 
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fabrication 
SC70 HT Solvent casting 2,5g 
PLLA 70ml chloroform 
Annealing 80°C 14h 
post fabrication 
SC70 HTAR HT Solvent casting 2,5g 
AFTER pellets 
treatment  PLLA 70ml 
chloroform 
Pellets heated at 80°C 
under argon 
atmosphere 2h pre 
fabrication and 
annealing 80°C 14h 
post fabrication 
Table9. Film names and description 
3.2.1. Aspect 
With SC70 HTAR, the films we obtained did indeed present better surfaces with less bubbles 
and more transparency.  
SC70 HT and SC70HTAR HT films appeared a lot more rigid and less transparent compared 
to films without annealing after fabrication (SC70 and SC70 HTAR films). 
 
Figure44. SC70 HTARHT film 
3.2.2.  SEM 
For the SEM images, all samples were carbon coated and the magnification used was x500. 
The two faces of the film present differences, then , it will be distinguished the face in contact 
with glass during fabrication, the bottom, and the opposite face  that wasn’t in contact with 
glass, the top.   
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Figure45. Image obtained by SEM of series Com. Bar: 20 um  
 
Figure46. Image obtained by SEM of the bottom side of series SC70 HTAR. Bar: 20 um  
 
Figure47. Image obtained by SEM of the top side of series SC70 HT. Bar: 20 um 
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Figure48. Image obtained by SEM of the bottom side of series SC70 HT. Bar: 20 um 
 
Figure49. Image obtained by SEM of the top side of series SC70 HTAR HT. Bar: 20 um 
 
Figure50. Image obtained by SEM of the bottom side of series SC70 HTARHT. Bar: 20 
um 
     
SEM images of the bottom sides of the different films series show a smoother surface. 
Contrary, the top side of our films show bubbles probably due to chloroform evaporation.  
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Annealing after fabrication seemed to make little difference on the morphology of the films 
although the surface does seem rougher with small cracks appearing. Films made from 
PLLA pellets with heat treatment under argon atmosphere appear to have fewer bubbles as 
is the case Figure 46, but Figure49 and 50 show many indicating heterogeneity of the 
process.  
3.2.3. EDS 
EDS analysis was used to detect chloroform residue on the films which should be avoided 
due to the toxic effect on cells. 
 
Figure51. General spectra of EDS showing position of chlorine  
The three strips (two red and one green) show us the position of chlorine on the following 
EDS graphs. The presence of chlorine (Cl) in our films indicates if there are any chloroform 
residues. 
 
Figure52. EDS analysis of SC70 HT. The strip indicates the position of chlorine 
 
Figure53. EDS analysis of Com 
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Figure54. EDS analysis of SC70 HTAR 
 
Figure55. EDS analysis of SC70 HTAR + HT 
All films without annealing after fabrication have chlorine due to residual chloroform whereas 
all films with annealing are chlorine free. Therefore, for our application all films must be 
annealed after fabrication to evaporate all the chlorine trapped in the film and be non-toxic 
for cells. This will be verified during the cytotoxicity test. The commercial film also has 
chlorine. Pre-treatment under argon also shows chlorine residue with no annealing after 
fabrication. 
3.2.4. White-light interferometry 
White light interferometry was used to verify that the roughness of our samples after the 
treatment didn’t increase considerably. Again we checked the roughness of both sides of the 
solvent casting films, the bottom in contact with the glass and the top not in contact with 
anything. 
  Sa(nm)±SD Sz(nm) ±SD 
   Top Bottom  Top Bottom 
SC70 HT  451,10±222,84 236,00±120,31 4708,15±1897,58 2382,31±692,82 
Table10. Roughness parameters obtained by interferometry for SC films with 
annealing. Mean values ± standard deviation  
 
Fabrication and surface modification of PLLA films for cardiovascular applications Pag. 53 
 
 
 
  
Sm ±SD(mm3/m2) SAreaIndex ±SD 
   Top Bottom  Top Bottom 
SC70 HT  22,33±14,93 19,33±10,30 1,07±0,04 1,04±0,04 
Table11. Roughness parameters obtained by interferometry for SC films with 
annealing. Mean values ± standard deviation  
  
Figure56. Comparison Sa(nm) top and bottom SC70 and SC70 HT by interferometry 
The roughness of our samples increased with heat treatment. This is due to the fact our films 
changed it structure as it became more rigid and transparent after annealing. Also the 
standard deviation is very high which shows again heterogeneity with the samples. 
The other parameters follow the same trend as Sa. 
3.2.5. Contact angle 
In this part we studied the wettability of all our annealed films and the surface free energy. 
  
CA(°) water CA(°) diiodomethane 
   Top Bottom  Top Bottom 
SC70  87,06±2,15 76,72±1,81 19,04±3,22 22,05±3,49 
Table12. Contact angle with water and diiodomethane of the annealed films. Mean ± 
standard deviation 
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Figure57. Contact angle with diiodomethane comparison SC and SC HT. Mean ± 
standard deviation 
 
  
Figure58. Contact angle with water comparison SC and SC HT. Mean ± standard 
deviation 
Heat treatment has little impact on contact angle as we can see through these two graphs. 
No general rule can be determined as sometimes contact angle increases slightly and in 
other cases decreases slightly after heat treatment. 
 SC70 HT 
SFE (mJ/m2) ± SD Top Bottom 
Dispersive 47,997±0,97 47,085±1,24 
Polar 0,715±0,29 3,177±0,55 
Total 48,713±1,07 50,262±1,26 
Table13. Surface free energy SC70 HT films using Owens and Wendt approach 
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Figure59. Surface free energy SC70 HT films Top using Owens Wendt approach 
 
Figure60. Surface free energy SC70 HT films Bottom using Owens Wendt approach 
We obtain similar results with the top and the bottom side of the films like with contact angle. 
The three films have similar surface free energies although SC70 05/11 has a slightly lower 
polar component. The bottom side of each film seems to have a slightly higher polar 
component. 
3.2.6. DSC 
The following step was to evaluate the cristallinity percentage of our chloroform solvent 
casting films after heat treatment. 
After treatment, we are expecting the percentage to be higher [69] [70]. 
 ΔHc (J/g) ±SD ΔHf (J/g) ±SD % Cristallinity±SD 
SC70 HT  0±0 24,97±3,54 26,84±3,81 
Table14. % Cristallinity results SC70 HT obtained by DSC 
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Figure61. %Cristallinity comparison SC70 films with and without annealing 
As expected, after annealing the cristallinity percentage of our films has increased. 
3.2.7. Mechanical test 
In this section we evaluated the mechanical properties of selected films. The mechanical 
parameters evaluated were high ultimate tensile strength (UTS in MPa) and a high young 
modulus (E in GPa). 
The first step was to cut the film into strips according to the standard D 882 – 02 [78]. 
Previous to the experiment, we measured the length, the width and the thickness of all the 
samples.  
The length of all specimens was measured and, the thickness was measured in five different 
places along the specimen. 
We wanted to verify the effect on annealing on mechanical properties. To do so, we 
prepared samples for mechanical assays of SC70 HTAR films which were made at the same 
time in exactly the same experimental conditions. One film was annealed at 80°C for 
14hours the other was not. We also tested the commercial film.  
 Length (mm) Width (mm)±SD  Thickness (um) )±SD 
SC70 HTAR 1 128 9,33±1,15 80±13,22 
SC70 HTAR 2 128 10,33±0,57 78,33±10,40 
SC70 HTAR 3 128 9,66±0,57 81,66±14,43 
SC70 HTAR 4 127 10,33±0,57 78,33±12,58 
0
5
10
15
20
25
30
35
40
SC70 Com
%
C
ri
st
al
lin
it
y 
without
annealing
with
annealing
Fabrication and surface modification of PLLA films for cardiovascular applications Pag. 57 
 
 
 
SC70 HTAR 5 129 11±1 80±5 
SC70 HTAR 6 130 9,66±0,57 76,66±15,27 
SC70 HTAR 7 127 8,2±0,76 78,33±12,5 
SC70 HTAR+HT 1 130 11,33±0,57 85±22,91 
SC70 HTAR+HT2 130 10±0 90±20 
SC70 HTAR+HT3 131 11,33±0,57 98,33±22,54 
SC70 HTAR+HT4 130 8,83±0,76 86,66±25,16 
SC70 HTAR+HT5 129 11,83±0,76 81,66±24,64 
SC70 HTAR+HT6 130 9,33±0,57 98,33±12,25 
SC70 HTAR+HT7 131 9,66±0,57 101,66±25,65 
Commercial film 1 129 9,5±0,5 48,33±2,88 
Commercial film 2 130 9,5±0,5 48,33±2,88 
Commercial film 3 131 8,66±0,57 50±0 
Commercial film 4 128 10,33±0,57 50±0 
Commercial film 5 129 9,33±0,28 48,33±2,88 
Commercial film 6 130 11±1 48,33±2,88 
Commercial film 7 130 10±0 50±0 
Commercial film 8 131 11±1 50±0 
Table15. Sample geometry for mechanical testing 
After all measures are completed, we then proceeded to calculate the young modulus E 
(GPa) for every strip and report the ultimate tensile strength UTS (MPa). 
According to DSC results, the samples with annealing should have higher mechanical 
properties than the films without due to a higher percentage of crystallinity. Also, we have no 
information on how the commercial film was made and if it received any sort of heat 
treatment like annealing. We calculated the Young modulus and tensile strength for all 
samples and reported the means and the standard deviation in the following table18. 
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 E (MPa)±SD UTS (MPa) ±SD 
SC70 HTAR 533,67±192,39 28,88±5,16 
SC70 HTAR HT 2847,72±535,41 62,58±10,76 
Com 3503,47±211,09 56,53±5,71 
Table16. Young modulus E (GPa) and ultimate tensile strength UTS (MPa) 
The Young modulus and the tensile strength of the commercial film are in accordance with 
the properties given to us by Goodfellow Cambridge Limited. The cristallinity of the 
commercial film is higher than the other two which explains a higher Young modulus. Tensile 
strength is slightly higher for SC70HTAR HT than the commercial film but the deviation is 
quite high.  
 
Figure62. Stress strain curve for commercial film sample one 
 
Figure63. Stress strain curve for SC70 HTAR film sample two 
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Figure64. Stress strain curve for SC70 HTAR HT film sample seven 
 
Figure65. Young modulus E in GPa obtained from tensile testing 
  
Figure66. Ultimate tensile strength TS in MPa 
As expected, both Young modulus and ultimate tensile strength are much higher after 
annealing.  
For a metal stent made of stainless steel, the young modulus and the ultimate tensile 
strength are much higher (UTS: 600 MPa, E: 200 GPa) than with our material [71]. But for a 
fully biodegradable PLLA polymer such as the IGAKI-TAMAI stent our results after annealing 
are within the top end of the branch (UTS= 15-150MPa; E = 2,7-4,14 GPa) [72]. 
These mechanical tests were rather hard to carry out for several reasons. Even though the 
samples were correctly jammed in carbon paper grips, slippage occurred and was 
complicated to avoid. If the grips were too tight, either at the top or the bottom, our sample 
would break prematurely at the grip. If the grips were too loose, the sample would slide out 
after initial stretching and would simply come out completely of the grip. This could induce 
errors during our measurements and could explain for example the difference in Young 
modulus for the same film. 
Also, after annealing our film became much more rigid which explains why the samples after 
annealing broke almost instantly once they reach the plastic domain compared to the films 
without annealing who usually at least doubled their length before rupturing. 
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3.2.8. Cytotoxicity 
In this part we verified the toxicity of our films thanks to the indirect cytotoxicity LDH test. 
Solution % living cells ± SD 
 SC70 SC70 HT SC70 HTAR 
Pure extract 3±0 84±8 45±52 
Ext/2 43±12 104±4 70±26 
Ext/10 96±21 99±10 67±24 
Ext/100 75±10 106±6 79±32 
Ext/1000 98±20 99±4 94±24 
Table17. LDH results 
 
Figure67. %living cells SC70 
 
Figure68. %living cells SC70 HT 
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Figure69. %living cells SC70 HTAR 
The films without annealing after fabrication are toxic. The percentage of living cells drops 
considerably. According to the standard, our films are cytotoxic if there are less than 30% 
living cells. After annealing, our films are not toxic as the heat treatment has got rid of all the 
residual chloroform which confirms the EDS results. 
 
3.3. Surface treatment 
In this part, we evaluated the properties of films after different surface treatments planned to 
generate COOH groups to increase cell adhesion. The objective was to check which one 
was most effective and had a less damaging effect on our films. The selection was based on 
structural and mechanical properties. 
 In order to increase the presence of carboxylic groups on our film surface, we did surface 
treatment on the fabricated films: NaOH, plasma and ozone. 
All films were made at the same time under the exact same conditions. They were all SC70 
HTAR HT films, procedure: (1) pellets heated at 80°C under argon atmosphere 2h; (2) 
Solvent casting 2,5g PLLA 70ml chloroform; and (3) film annealing 80°C 14h. Each surface 
treatment was done on separate films. 
Name Surface treatment 
No NaOH  
1h NaOH immersed in NaOH 
1M for 1h at 37°C 
3h NaOH immersed in NaOH 
1M for 3h at 37°C 
5h NaOH immersed in NaOH 
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1M for 5h at 37°C 
No ozone  
20min ozone 20min ozone 
treatment 
40min ozone 40min ozone 
treatment 
1h ozone 1h ozone treatment 
No plasma  
30s plasma 30s plasma 
treatment 
2min plasma 2min plasma 
treatment 
5min plasma 5min plasma 
treatment 
Table18. Obtained film names 
3.3.1. Contact angle 
Contact angle was performed on the three samples as well as a sample of the same film 
without any treatment. Contact angle is sensitive to any surface change; an activation 
treatment should induce a decrease of the contact angle probable due to the increase of 
COOH and OH groups. To control the time needed for each surface treatment process, it 
has been studied the contact angle at different times for each treatment. When the CA 
obtains a plateau value, we consider that we have reached the stability of the treatment and 
that more time of application does not mean an increase of the COOH and OH groups 
[74][75]. 
It is important that measures of all samples are on the same surface (top or bottom). During 
the cutting of the samples, they were marked with a Stanley knife to avoid mistakes and 
confusion. 
Contact angle was calculated with distilled water (MilliQ). Ten measures have been 
performed for each sample. 
 No NaOH 1h NaOH 3h NaOH 5h NaOH 
CA (°)±SD 99,12±1,57 103,75±0,66 98,39±1,61 84,25±4,27 
Table19. Contact angle (°) with water for NaOH treated samples 
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Figure70. Contact angle (°) with water for NaOH treated samples 
There is a change in the contact angle only after 5hours compared to our sample which 
hasn’t been treated. Therefore the treatment is only effective after 5hours. 
 No ozone 20min ozone 40min ozone 1h ozone 
CA (°)±SD 79,32±3,2 57,73±2,92 54,32±1,81 54,88±1,69 
Table20. Contact angle (°) with water for ozone treated samples 
 
Figure71. Contact angle (°) with water for ozone treated samples 
After 20 min of ozone treatment, the contact angle does not vary. Then it was selected a 
time of 20 min for this treatment.  
 No plasma 30s plasma 2min plasma 5min plasma 
CA (°)±SD 102,97±1,50 92,85±1,06 72,44±6,48 66,03±2,76 
Table22. Contact angle (°) with water for ozone treated samples 
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Figure72. Contact angle (°) with water for plasma treated samples 
For plasma surface treatment, after 2 min of exposure, the wettability does not change 
significantly. The surface seems to be saturated after 2min of treatment according to these 
values.  
3.3.2. Aspect 
For plasma and NaOH treated films whatever the length of the treatment, the surface 
appeared exactly the same as without the treatment.  
For ozone treated films, after 20 min of exposure the film was already damaged. Many 
cracks appear on the films after 20 min and as increases the exposure time, the film damage 
is higher. 
3.3.3. SEM 
  
Figure73. SEM image of the no ozone Top series. Bar: 20 um 
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Figure74. SEM image of the no ozone Bottom series. Bar: 20 um 
  
Figure75. SEM image of the 20min ozone Bottom series. Bar: 20 um   
 
Figure76. SEM image of the 20min ozone Top series. Bar: 20 um 
For the ozone treated film, we can see fewer bubbles independently if it’s the top or the 
bottom of the film. However, the bottom side has cracks which seem to be due to the 
generated heat by the ozone treatment which deteriorates our films. The film was subjected 
to ozone treatment for 20min which must have been too long as our film afterwards were 
massively damaged and cracked. The top side also has cracks but the area we chose didn’t 
to highlight the cleaning effect of the ozone treatment. 
3.3.4. White-light interferometry 
 
no NaOH NaOH 1h NaOH 3h NaOH 5h 
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Sa(nm)±SD 582,35±211,10 228,08±107,11 145,63±45,13 219,04±79,22 
Sz(nm) ±SD 4793,39±536,77 2668,38±782,81 1822,30±355,16 2811,10±501,79 
Sm ±SD(mm3/m2) 43,6±17,9 28,2±13,3 19,9±6,77 11±2,5 
SAreaIndex ±SD 1,13±0,02 1,06±0,02 1,02±0,01 1,15±0,05 
Table23. Roughness parameters for NaOH treated samples at different exposure times 
obtained by interferometry 
  
Figure77. Roughness Sa (nm) for NaOH treated samples 
The mean roughness of the samples seems to decrease as increases the exposure time for 
NaOH treatment.  
 
no ozone 20min ozone 40min ozone 1h ozone 
Sa(nm)±SD 553,26±292,61 680,72±123,94 981,07±298,05 640,44±505,59 
Sz(nm) ±SD 5318,41±1866,05 4648,81±712,34 6785,84±229,41 4561,50±3666,21 
Sm ±SD(mm3/m2) 34±19,6 35,6±19,2 59,9±30,9 43,3±28,7 
SAreaIndex ±SD 1,09±0,06 1,03±0,02 1,04±0,02 1,04±0,06 
Table24. Roughness parameters for ozone treated samples at different exposure times 
obtained by interferometry 
  
Figure78. Roughness Sa (nm) for ozone treated samples 
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Roughness seems to increase as increases the exposure time to ozone treatment. The 
longer the samples are treated the higher the roughness. The values after 1 hour exposure 
are lower but it seems due to a problem during contact angle measurements since the 
standard deviation is huge. We expected an increase of roughness  after 1 hour of 
treatment. This is due to the fact that during ozone treatment, the samples are submitted to 
important UV action and an increase in temperature, which deteriorates the surface of our 
samples. 
 
no plasma 30s plasma 2min plasma 5min plasma 
Sa(nm)±SD 999,76±277,14 867,10±247,48 354,99±192,34 510,80±132,13 
Sz(nm) ±SD 6727,39±1877,39 6849,98±1248,88 3091,50±1223,11 4065,61±799,07 
Sm ±SD(mm3/m2) 46,6±19,7 49,5±16,3 29,8±22,3 34,2±15,8 
SAreaIndex ±SD 1,07±0,03 1,06±0,01 1,03±0,01 1,04±0,01 
Table25. Roughness parameters for plasma treated samples at different exposure 
times obtained by interferometry 
 
Figure79. Roughness Sa (nm) for plasma treated samples 
The roughness of our samples decreases thanks to plasma treatment. This is due to the 
cleaning effect of plasma treatment. After 5 min of plasma exposure, roughness is slightly 
higher than after 2 min.  
3.3.5. DSC 
 
no NaOH 1h NaOH 3h NaOH 5h NaOH 
Weight (mg) 11,11 11,54 13,61 12,75 
%cristallinity 26,44 23,21 21,34 22,31 
Table26. Critallinity percentage of NaOH treated samples by DSC 
During NaOH surface treatment, %cristallinity doesn’t change much. 
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no ozone 20min ozone 40min ozone 1h ozone 
Weight (mg) 11,38 12,09 10,35 13,69 
%cristallinity 30,48 32,20 39,19 42,34 
Table27. Critallinity percentage of ozone treated samples 
 
Figure80. % cristallinity of ozone treated samples by DSC 
The cristallinity percentage increases as increases the exposure to ozone. During the 
treatment, there is an increment of temperature which could act like an annealing process 
and, therefore, increase in the percentage of cristallinity.  
As seen before, this rise in temperature is good for the cristallinity which is related to 
mechanical properties but the surface of our samples is quite massively deteriorated. As we 
can ress from the… results  
 
no plasma 30s plasma 2min plasma 5min plasma 
Weight (mg) 11,61 12,67 11,05 11,36 
%cristallinity 24,63 28,16 26,30 24,02 
Table28. Critallinity percentage of plasma treated samples 
The cristallinity percentage of the samples during plasma treatment didn’t change 
significantly. 
3.3.6. Cytotoxicity 
Cytotoxicity test was done on a SC70 HTAR HT sample and a sample from the same film 
with NaOH treatment for 3h to evaluate the toxicity of this treatment. Plasma and ozone 
treatment shouldn’t have an effect on toxicity.  
Solution % living cells ± SD 
 No NaOH 3h NaOH 
Pure extract 100±8 80±36 
Ext/2 83±2 108±4 
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Ext/10 81±4 135±8 
Ext/100 100±12 146±14 
Ext/1000 91±8 123±22 
Table29. LDH results 
 
Figure81. %living cells no NaOH 
 
Figure82. %living cells 3h NaOH 
NaOH activated film is toxic with the pure extract. The cleaning of the film after the NaOH 
etching needs to be incremented in order to avoid residual NaOH on the film. 
3.3.7. GPC 
We measured three different parameters for each sample with the GPC technique:  
 Number average molar mass or Mn 
 Mass average molar mass or Mw 
 Z average molar mass or Mz 
 Mass (mg) Mn (g/mol) Mw (g/mol) Mz (g/mol) 
Stent 1,90 65312 191010 357390 
PL65 Pellet 1,69 448730 1401400 3337400 
SC70HTAR HT 1,79 615560 1506900 2673800 
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5 
NaOH 3h 0,55 557110 1427700 2516800 
Ozone 1h 1,56 4090 21875 74576 
Plasma 2min 0,92 606100 148690 2714600 
Table30. GPC results 
NaOH 3h, the sample with no surface treatment and plasma 2min have practically the same 
results indicating a no significant effect of the mentioned surface treatments on the original 
film.  
 The pellet has slightly lower values  except average molar mass Mz which is slightly higher. 
This is due to the fact our samples were annealed after fabrication which increases the 
cristallinity.  
The ozone sample is clearly damaged as seen with the SEM which explains these results 
which are much lower than the others. 
Other than the ozone sample, all samples have higher values than the stent and than the 
PL65 pellet.  
3.3.8. Conclusion 
According to results, plasma surface treatment seems to be the best for our application 
because of minimisation of thermal degradation and the short treatment time. Indeed, the 
surface aspect stays the same while roughness diminishes at first thanks to the cleaning 
effect from the plasma treatment then seems to increase after 5min. Ozone treatment 
damages considerably our films already after 20min but the surface is saturated in OH 
groups. NaOH could be a surface activation treatment option but the cleanings are very 
important in order to eliminate all the cytotoxic residuals. 
Further studies for shorter times need to be conducted to be able to judge which surface 
treatment is the most effective between ozone and plasma for our application. 
3.4. Polymer degradability 
We compared the degradation of five films with the degradation of a fully biodegradable 
stent. As we know how long this stent is going to take to fully degrade (two years), we chose 
five films and placed them in solutions of NaOH 1M and took them out at different times over 
a period of one week. The films we used were: commercial, solvent casting 70ml chloroform 
with annealing afterwards (80°C for 14h), 70ml chloroform with pellets treated at 80°C under 
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argon atmosphere, same but with annealing after and 70ml chloroform with annealing and 
plasma treatment. 
The stent we used is called Remedy Biodegradable Peripheral Stent and is from Kyoto 
medical planning in Japan. 
Unfortunately, the test didn’t work as we expected. The concentration of NaOH we used 
(1M) was too high and all our samples were almost totally dissolved in the solution after two 
days. The stent as also totally dissolved.  
We repeated the test but this time with a NaOH concentration of 0,1M instead. 
The test wasn’t done in time to report the results here. 
4. General discussion 
The main aspect of this project was to determine a  fabrication method of PLLA films to then 
characterise them chemically, physically and mechanically to be able to use this material in 
the future as a totally biodegradable cardiovascular stent.  
Concerning the film fabrication, there are advantages and disadvantages with each 
technique. Hot pressing is less time consuming,the overall process takes around 10 hours), 
there is no use of solvents and films are nontoxic. We expected to obtain films with best 
mechanical properties, compared to solvent casting process, due to a higher cristallinity. 
Unfortunately we could not do mechanical tests on our hot pressing films as the films were 
too small in respect to the standard.But on the other hand, films with a good surface aspect 
are harder to obtain. 
With hot pressing, many parameters can change and may influence the surface aspect of 
our film such as: more or less holes, larger and flatter surface, different thickness across the 
film and cleanness. We tried several different protocols and we never obtained a perfectly 
suitable film. And with for the films fabrication, reproducibility is also an issue. 
With solvent casting technique, film fabrication takes much longer. Depending on the 
protocol, it can take several days. The obtained films present a better surface aspect: 
homogeneous, same thickness in all points of the film, clean and transparent. There tends to 
be no holes but bubbles can be a major issue. Chloroform trapped in the film can induce cell 
cytotoxicity. 
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SEM indicated that the bubbles were generally on the top part of the solvent casting films 
instead of the bottom part which is much smoother and with few bubbles. This was verified 
with white light interferometry, the roughness of the solvent casting films was much higher 
on the top part than on the bottom part in contact with the glass during fabrication.  
The roughness on the bottom of solvent casting films was also much lower than hot pressing 
films we made (artisanal or conventional). The top part depended on the amount of 
chloroform due to chloroform evaporation and presence of bubbles.  
However, cristallinity was much higher with artisanal hot pressing films than with solvent 
casting films that was expected as no solvent is used. Although mechanical tests were not 
performed on hot pressing films, we expect higher tensile strength and a higher Young 
modulus than with solvent casting films due to higher cristallinity. Nevertheless, hot pressing 
technique was discarded as a film fabrication technique in this project, due to the poor 
reproducibility we found in the presented conditions. 
Contact angle measures showed that the HP films (artisanal and conventional) were more 
hydrophobic than all the SC films. 
The solvent casting films with dichloromethane (70 ml and 100 ml) had poor surface 
morphology. They weren’t as transparent as chloroform films inducing problems for white 
light interferometry measurements. Other parameters such as contact angle and roughness 
were very similar to SC70 films and therefore better than HP films. Cristallinity of films 
performed with dichloromethane as solvent were very disparate even though they were 
fabricated at the same time and in the exact same conditions. We chose not carry on with 
that solvent due to the heterogeneity of results between equal prepared films and cristallinity. 
The films we chose to carry on our investigation as they had the best overall properties were 
solvent casting with a concentration of 3,6% weight/volume chloroform., SC70 series.  
We also tried to perform heat treatment directly on the pellets before the film fabrication 
under argon atmosphere at 80°C for 2h to improve the surface morphology of our films and 
the aspect homogeneity. The films with this pre-treatment did indeed have fewer bubbles as 
we saw on SEM images.  
To eliminate chloroform residue, the films were annealed for 14 h at 80°C after fabrication. 
EDS and cytotoxicity tests with HUVEC cells indicated that the films had no chloroform lafter 
the treatment and were no cytotoxic for cells. 
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Annealing enabled the chloroform to evaporate fully. Cristallinity increased after annealing 
and then, the Young modulus and the tensile strength also increased. Roughness increased 
slightly but not significantly especially on the bottom side of our films which have the lowest 
roughness. Contact angle values nearly didn’t change after annealing.  
The following step in our research was to focus on surface activation treatments to increase 
the number of OH and COOH groups at the surface. 
The surface treatments applied were: ozone, O2 plasma and NaOH surface activation for 
different times. The first thing was to measure contact angle values straight after the 
treatments in order to select the time of treatment exposure in accordance with the stability 
of the contact angle. Finally times of 20 min for ozone, 2 min for plasma and 5 h for NaOH 
where chosen. Then, we proceeded to measure the roughness and the cristallinity of all the 
samples to see the evolution of properties with different treatments and different times.  
O2 plasma, treated samples showed a roughness decrease during time due to the cleaning 
effect of plasma. Cristallinity didn’t vary during treatment and the film aspect also didn’t 
change during treatment.  
The ozone treated films were already damaged after 20 min and got worse during time of 
treatment. The films became very brittle due to the increase in temperature during ozone 
treatment. We verified the surface of the films thanks to SEM and we could see many cracks 
appear. The roughness increased during treatment time due to the degradation of the film 
and cristallinity also increased with treatment time due to the annealing effect of the 
treatment. For that reasons it was not a good surface treatment of activation for SC70 films.  
The roughness of NaOH treated surfaces seem to decrease with increasing time of 
exposure and cristallinity didn’t change. Cytotoxicity results showed that NaOH film are toxic 
with the pure extract and concluded that the cleaning of the film after the NaOH etching 
needs to be better to avoid residual NaOH on the film. 
GPC tests indicated the molecular weight change of surface treated PLLA films and 
compared to commercial stent and the raw PLLA PL65 pellet as well as the sample with no 
surface treatment. All samples were taken from the same film.  
NaOH, plasma and the sample with no surface treatment showed the same molecular 
weight that was slightly higher than the stent and the PL65 pellet. The ozone treatment 
damaged the sample heavily and therefore had very low values. From this part, we 
concluded the best surface treatment for our films was plasma during 2 min. 
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5. Conclusion 
Enhancing PLLA film fabrication was our main focus point during this project to be able to 
characterise them and make a parallel with fully biodegradable stents made with the same 
polymer.  
Firstly we made films using different techniques hot pressing and solvent casting with 
different solvents. Then we characterised them with contact angle, white light interferometry 
and DSC in order to choose the best film fabrication process for our application. 
Once we chose the fabrication process, we focused on improving the films (aspect and 
properties) with different heat treatments pre and post fabrication. We found that doing a 
heat treatment on the PLLA pellets under argon atmosphere and annealing post fabrication 
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had good results for the properties and for the aspect of the films. Annealing post fabrication 
was in fact essential due to chloroform residue which renders our films cytotoxic and 
therefore lethal for human cells. Annealing post fabrication also increased cristallinity and 
mechanical properties which is an important factor for stent implantation in the human body. 
Then we went on to verify which surface treatment was the best for our films (properties 
aspect) to create hydroxyl groups for cell adhesion. We found that plasma surface treatment 
was optimal for our PLLA films as roughness decreased due to cleaning effect of the 
technique and general aspect of our films remained the same.  
Finally we checked molecular weight of films with heat treatment pre and post fabrication 
and also with surface treatments and compared it to PL65 pellets and a fully biodegradable 
stent made of PLLA and verified our films had higher molecular weight than both of them.  
Our main difficulty throughout the project was with reproducibility as results we obtained 
were very often disparate.  
Future research should go in the direction of enhancing film fabrication even further and also 
the efficiency of surface treatment. 
 
 
 
 
6. Environmental impact 
The environmental impact of the project is due to the utilization of electricity, water, and 
chemical reactives. Because of this, at each moment, it has been intended to minimise the 
quantity of resources, realise a correct management of the residues and adopt the 
necessary security means (gloves, lab coat, glasses and so on) in accordance with the 
material safety data sheets (MSDS).   
The experiments have been performed in the laboratory of Biomaterial of the Escola Tècnica 
Superior d’Enginyeria de Barcelona (ETSEIB) and in the installation of the institute of 
bioengineering of Catalonia (IBEC) situated in the Scientific Park of Barcelona. In both 
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places, the management of the residues and the storage of the reactive have been done in 
accordance with the internal rules.   
In the UPC laboratory of biomaterials, the residues are eliminated in different waste disposal 
following their nature:   
- Non halogenated solvents (acetone, ethanol): in a 10 l can of polypropylene (PP)  
- Specific waste are collected separately (diiodomethane)   
The full recipients are stocked in a security cupboard and each 6 months, the ECOCAT firm 
collects the laboratory wastes and realizes the process of waste management.  The rest of 
the work has been performed in the Parc Cientific de Barcelona where the residues are 
classified and dropped in:    
- Acid solutions (pH<7) with concentration lower than 10% (organic and inorganic acids): in a 
5 l can of polypropylene (PP)  
- Alkaline solutions (pH>7) with concentrations lower than 10%: in a 5 l can of polypropylene 
(PP)  
-  Non halogenated solvents (alcohols, aldehydes, ketones, amides, ethers): in a 5 l can of 
polypropylene (PP)   
- Halogenated solvents (solvents with F,Cl, Br, and I): in a 5 l can of polypropylene (PP)  
- Specific waste must be collected separately (Cyanide, some peroxides): can for each kind  
- Solid waste (dirty paper, gloves, broken glass, plastic petri dishes and so on)   
- Sharp or pointed objects items contaminated that can cut or pierce (needles, pipettes tips 
and so on)  
The collect of the waste cans is weekly realized by the personnel of the Parc Cientific de 
Barcelona.   
The other equipment used during this project is subjected to periodical revisions.   
Finally, energy consummation is unavoidable and directly linked to CO2 emissions. 
However, it results to be difficult to quantify this impact because it is tough to quantify the 
consummation of each technique and general activity in the laboratory. In each moment, a 
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rational use of paper and water has been made, as well as useless impressions or copies 
have been avoided.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
7. Costs 
The present section presents the global cost of this project. The economic study promotes 
the time equipment was used, human resources and the material costs. The reference 
prices have been obtained from the fee published by the Serveis Cientificotècnincs of the UB 
and the Grupo de Biomateriales des Departamento de Ciencia de Materiales e Ingenieria 
Metalurgica of the UPC.  
With regard to personnel, it has been estimated:   
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- The dedication of the tutor has been approximated to 8 hours a month with a level of fees 
corresponding to a Project Chief Engineer.  
-The involvement of doctoral students is estimated to 20 h a month. For the level of fees the 
doctoral student will be considered as Senior Engineer.  
-The work done by the author of this report includes analysis of the problem, bibliographic 
research, and elaboration of the report and corresponds to 160 hours a month. The fees are 
calculated based on a Junior Engineer.  
-The use of all instruments and test equipment needs support of personnel. The intervention 
of technicians is essential for the proper use of different machines and the proper functioning 
of the laboratory. The involvement of laboratory technicians is estimated to 20 hours per 
month. 
Concept Quantity Price Cost (€) 
Preparation and cleaning of the samples 
Chloroform 2,5l 108€/5l 54 
Dichloromethane 500ml 54€/l 27 
PLLA PL65 100g 2820€/kg 282 
Acetone 2l 16,65€/l 33,3 
Ethanol 96% 2l 25,50€/l 51 
  Total 447,3 
Surface treatments and degradation 
O2 plasma 10 8,63€/sample 86,3 
NaOH 50g 51,58€/500g 5,2 
Ozone 10 8,63€/sample 86,3 
Syringe 10ml 50 7€/100 units   3,5 
Syringe 1 ml 50 6€/100 units 3 
Needle 80 units 5€/40 units   10 
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Plastic flask 10 35,47€/400 units 1 
Plastic tube 50 74.77€/500tube 7,5 
Plastic tips for pippetes 500 units 8,2€/1000 units   4,1 
Kimwipes professional paper  1/2 box 33€/box   16,5 
  Total 223,4 
Characterisation 
Contact Angle 30h 35€/h   1050 
Diiodomethane  3ml 40,2 €/40ml 3 
SEM 4h 48€/h   192 
White-light interferometry   30h 35€/h 1050 
Optical microscopy 1h 20€/h 20 
Plate-reader 1h 40€/h 40 
LDH Kit 4 235€/400 assay  2,35 
HUVEC cells 1 450€/cryovial 450 
EMB-2 100ml 127€/500ml 25,4 
FBS 40ml 474€/500ml 38 
PBS 200ml 10€/500ml 4 
Plastic Flask 10 30€/flask 300 
24-well plate 15 46, 50€/50units 13,95 
48-well plate   20 99,75€/75units   26,6 
96-well plate 6 52,2€/50unit 6,2 
DSC 30 35€/h 1050 
GPC 6 300€/sample 1800 
  Total 6071,5 
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Material and personnel 
Office material, printings, CD, files…   300 
Consumable lab material   150 
Common lab equipment, milliQ water, paper, pliers…   100 
  Total 550 
Fees for specialized personnel (4,5 months) 
Junior Engineer 720h 20€/h 14400 
Senior Engineer 140h 30€/h 4200 
Project Chief Engineer 30h 60€/h 1800 
Laboratory technicians 140h 25€/h 3500 
  Total 23900 
  Subtotal 31192,2 
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